Abstract:Viral respiratory infections are of major importance because of their capacity to cause of a high degree of morbidity and mortality in high-risk populations, and to rapidly spread between countries. Perhaps the best example of this global threat is the infectious disease caused by the new SARS-CoV-2 virus, which has infected more than 4 million people worldwide, causing the death of 287,000 persons according to the WHO's situation report on May 13, 2020. The availability of therapeutic tools that would be used massively to prevent or mitigate the detrimental effects of emerging respiratory viruses on human health is therefore mandatory. In this regard, research from the last decade has reported the impact of the intestinal microbiota on the respiratory immunity. It was conclusively demonstrated how the variations in the intestinal microbiota affect the responses of respiratory epithelial cells and antigen presenting cells against respiratory virus attack. Moreover, the selection of specific microbial strains (immunobiotics) with the ability to modulate immunity in distal mucosal sites made possible the generation of nutritional interventions to strengthen respiratory antiviral defenses. In this article, the most important characteristics of the limited information available regarding the immune response against SARS-CoV-2 virus are revised briefly. In addition, this review summarizes the knowledge on the cellular and molecular mechanisms involved in the improvement of respiratory antiviral defenses by beneficial immunobiotic microorganisms such as Lactobacillus rhamnosus CRL1505. The ability of beneficial microorganisms to enhance type I interferons and antiviral factors in the respiratory tract, stimulate Th1 response and antibodies production, and regulate inflammation and coagulation activation during the course of viral infections reducing tissue damage and preserving lung functionally, clearly indicate the potential of immunobiotics to favorably influence the immune response against SARS-CoV-2 virus.

Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?

Induction of protective immune responses at respiratory mucosal sites

Induction of Mucosal Immunity Through Systemic Immunization: Phantom or Reality?

ORAL ROUTE AS METHOD FOR IMMUNIZING AGAINST MUCOSAL PATHOGENS

Vaccine Strategies to Elicit Mucosal Immunity

Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut–Lung Axis: Future Possibilities for SARS-CoV-2 Protection

Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases

Mucosal adjuvants

Oral administration of immunomodulators and the mucosal immune system.

Advanced Oral Vaccine Delivery Strategies for Improving the Immunity

Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities

Advancedoral vaccine delivery strategies for improving the immunity.

Biomaterial Approaches for Understanding and Overcoming Immunological Barriers to Effective Oral Vaccinations

Probiotics, antibiotics and the immune responses to vaccines

[Mucosal immunity and vaccines against viral infections]

The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA

Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa

The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?

Host Functional Response to a Prototypic Orally Delivered Self-Replicating Vaccine Platform